The Brazilian health system, Sistema Único de Saúde (SUS), has announced an expansion in the use of the antibiotic doxycycline as a preventive measure against sexually transmitted infections (STIs), specifically syphilis and chlamydia. This decision was formalized through an official decree published by the Ministry of Health, enabling the use of doxycycline as post-exposure prophylaxis (PEP) after situations deemed high-risk, such as unprotected sexual intercourse.

According to the new regulations, SUS will have a period of up to 180 days to implement this new indication for doxycycline, ensuring that the distribution and administration of the medication are organized effectively. The rules under which the prophylactic treatment will be offered will be guided by a Clinical Protocol and Therapeutic Guidelines, which will outline the specific groups eligible for treatment and the circumstances under which PEP will be recommended.

Doxycycline has been a long-established antibiotic used for treating various bacterial infections and is now being repurposed in this context to help curb the incidence of two significant STIs. This approach aligns with contemporary healthcare practices that aim to mitigate the spread of infections through preventive measures, showcasing a proactive stance in public health management in Brazil.